Literature DB >> 30890768

High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.

Irene Prediletto1, Sarah A Farag1, Ulrike Bacher2, Barbara Jeker1, Behrouz Mansouri Taleghani2, Rachel Brégy3, Thilo Zander4, Daniel Betticher5, Thomas Egger6, Urban Novak1, Thomas Pabst7.   

Abstract

Entities:  

Year:  2019        PMID： 30890768     DOI： 10.1038/s41409-019-0508-2

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

Review 1.  Management of nephrotoxicity of chemotherapy and targeted agents: 2020.

Authors:  Varsha Chiruvella; Pavan Annamaraju; Achuta K Guddati
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  BeEAM High-Dose Chemotherapy with Polatuzumab (Pola-BeEAM) before ASCT in Patients with DLBCL-A Pilot Study.

Authors:  Tanja Stoffel; Ulrike Bacher; Yara Banz; Michael Daskalakis; Urban Novak; Thomas Pabst
Journal:  J Clin Med       Date:  2022-06-28       Impact factor: 4.964

3.  Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.

Authors:  Sarah Farag; Ulrike Bacher; Barbara Jeker; Myriam Legros; Gaelle Rhyner; Jean-Marc Lüthi; Julian Schardt; Thilo Zander; Michael Daskalakis; Behrouz Mansouri; Chantal Manz; Thomas Pabst
Journal:  Bone Marrow Transplant       Date:  2022-04-20       Impact factor: 5.174

4.  Bendamustine-induced nephrogenic diabetes insipidus - A case report.

Authors:  Audrey Desjardins; Viviane Le-Nguyen; Léa Turgeon-Mallette; Chloé Vo; Jean-Samuel Boudreault; Jean-Philippe Rioux; Xue Feng; Amélie Veilleux
Journal:  J Oncol Pharm Pract       Date:  2021-05-14       Impact factor: 1.809
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.